Provided by Tiger Fintech (Singapore) Pte. Ltd.

NVIDIA Portfolio

1,546.30
+69.264.69%
Number of Gainers:8
Number of Losers:- -
Number of Flat:- -
PE:- -
High:1,565.42
Open:1,481.83
Low:1,481.83
Close:1,477.04
Loading ...

Shares of AI-Based Drug Developers up on US FDA's Plans to Replace Animal Testing

THOMSON REUTERS
·
11 Apr

Recursion Pharmaceuticals up 9.3%, Absci up 10.9%, Schrodinger up 4.5% and Certara up 10.9%

THOMSON REUTERS
·
11 Apr

When Will SoundHound AI's Stock Return to Its High of $24?

Motley Fool
·
11 Apr

FirstEnergy's Pennsylvania Arm Finishes Upgradation of Electric System

Zacks
·
11 Apr

Reliance Industries Arm to Acquire Additional 10% Stake in Nauyaan Shipyard, Shares Up 3%

MT Newswires Live
·
11 Apr

Harley-Davidson Weighs Sale of Financing Arm, Sources Tell Bloomberg

Dow Jones
·
11 Apr

Recursion Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
11 Apr

Bread Financial (BFH) Surges 12.7%: Is This an Indication of Further Gains?

Zacks
·
10 Apr

Why ARM Holdings Plc (ARM) Went Up On Wednesday?

Insider Monkey
·
10 Apr

Biocon Arm Gets US FDA Nod for Oncology Drug Jobevne

MT Newswires Live
·
10 Apr

Loongson Technology Says US Tariffs Will Not Hurt Operations

MT Newswires Live
·
10 Apr

Two Stock Disruptors in the Making: How Kaltura and Serve Robotics Are Shaping the Future

TIPRANKS
·
09 Apr

Stagwell (STGW) Unveils New SPORT BEACH 2025 Athletes and Brand Partners Including Erin Andrews, Sir Mo Farah, Chris Paul, Alex Rodriguez, George Russell, Charissa Thompson and More

PR Newswire
·
09 Apr

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

GlobeNewswire
·
09 Apr

BlackBerry's QNX Powers WeRide's ADAS Platform for Partially Automated Vehicles

MT Newswires
·
09 Apr

BlackBerry's QNX Collaborates With WeRide on Driver Assistance Systems

MT Newswires Live
·
09 Apr

Recursion Pharmaceuticals Doses First Patient in Phase 1 Trial of Potential B-Cell Lymphoma Treatment

MT Newswires Live
·
08 Apr

SATS' Arm Partners Airbus HBCplus Ecosystem as Managed Service Provider

Zacks
·
08 Apr

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of Rec-3565, a Selective Malt1 Inhibitor for Relapsed or Refractory B-Cell Lymphomas

THOMSON REUTERS
·
08 Apr

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

GlobeNewswire
·
08 Apr